Original ArticleCirculating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma
Section snippets
Background
Pancreatic cancer (PC) is the fourth leading cause of cancer-related death in the United States among both men and women. The majority of these tumors (85%) are adenocarcinomas arising from the ductal epithelium [1], [2]. PC has an extremely high mortality rate due to its aggressive metastatic nature. Factors derived from both genetic and surrounding microenvironment may contribute to this aggressive nature [3]. In PC, severe desmoplastic response is usually observed around the primary tumor [4]
Patients' characteristics
The recorded data of 33 patients with histologically confirmed diagnosis of PA, were treated and followed up in our clinic. Chemotherapy (CTx) was given to the majority of the patients with metastatic disease (n = 20, 61%). Drug schemes were applied as follows: combination of gemcitabine with platinum or capecitabine (n = 6 and n = 3), or gemcitabine alone (n = 11). Response to treatment was determined radiologically after 2–3 cycles of CTx according to revised RECIST criteria version 1.1. by
Results
From February 2010 to July 2013, 33 patients with a pathologically confirmed diagnosis of PA were enrolled in this study. The baseline histopathological characteristics and the demographic characteristics of the patients are listed in Table 1, Table 2. The median age at diagnosis was 59 years, range 32–84 years; majority of the patients in the group were men (n = 20, 61%). The tumor was located in the head of pancreas in 21 (64%) patients. Thirty-nine percent of the 23 metastatic patients who
Conclusion
Pancreatic cancer is a highly lethal malignancy, for which there are few viable therapeutic options. Because of the absence of effective methods for early detection and the aggressive nature of this disease, the majority of patients present with locally advanced or metastatic cancer not eligible for surgical resection [14]. Chemotherapeutic options for treatment of advanced pancreatic cancer are still limited. Gemcitabine has been the standard chemotherapeutic drug for patients with advanced
Conflict of interest
None declared.
References (19)
- Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin...
- et al.
Global cancer statistics
CA Cancer J Clin
(2011) - et al.
Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines
J Exp Med
(2015) - et al.
Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma
Cancer Cell
(2014) - et al.
Tumor progression: defining the soil round the tumor seed
Curr Biol
(2001) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators
Semin Cancer Biol
(2006)- et al.
Expression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancer
J Immunol
(2009) - et al.
Exploitation of interleukin-18 by gastric cancers for their growth and evasion of host immunity
Int J Cancer
(2006) - et al.
Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma
World J Gastroenterol
(2007)
Cited by (12)
The role of interleukin-18 in pancreatitis and pancreatic cancer
2019, Cytokine and Growth Factor ReviewsCitation Excerpt :On the other hand, Guo et al. [143] demonstrated a shorter OS for PDAC patients with lower IL-18 level in their serum. Finally, Usul et al. [142] showed no significant correlation between them. The different conclusions from the mentioned investigations may be resulted from the difference of recruited patients.
Anthocyanin composition of fruit extracts from Lycium ruthenicum and their protective effect for gouty arthritis
2019, Industrial Crops and ProductsCitation Excerpt :IL-18 represents an inflammatory cytokines that has long been described as featuring both pro-and anti-inflammatory properties. IL-18 is also related to gastric cancer, HIV, colitis, inflammation of the central nervous system, pancreatic adenocarcinoma, etc. (Allam et al., 2017; Afsar et al., 2017; Impellizzeri et al., 2018; Orhan et al., 2016; Nguyen and Putoczki, 2018). COX-1 represents the isoform of Cyclooxygenase (COX) enzymes.
Molecular Mechanisms of IL18 in Disease
2023, International Journal of Molecular Sciences